Seroepidemiology of hepatitis A among Greek children indicates that the virus is still prevalent: Implications for universal vaccination

Journal of Medical Virology

Volumn 81, Issue 4, 2009, Pages 582-587

  Kyrka, A ^a   Tragiannidis, A ^b   Cassimos, D ^c   Pantelaki, K ^d   Tzoufi, M ^e   Mavrokosta, M ^f   Pedeli, X ^a   Athanassiadou, F ^b   Hatzimichael, A ^c   Konstantopoulos, A ^a   Kafetzis, D ^a   Papaevangelou, V ^a,g  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d Ag Sophia Children's Hospital   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

^f Venizelos General Hospital   (Greece)

^g UNIVERSITY OF ATHENS   (Greece)

Author keywords

Hepatitis A; Seroepi demiology; Vaccine

Indexed keywords

HEPATITIS A VACCINE; IMMUNOGLOBULIN G; HEPATITIS A ANTIBODY;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; CHILD; DRUG SAFETY; DRUG TOLERABILITY; GREECE; HEALTH PROGRAM; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMIGRANT; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; RURAL AREA; SCHOOL CHILD; SEROEPIDEMIOLOGY; SEROLOGY; SEROPREVALENCE; VACCINATION; BLOOD; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; MALE; NEWBORN; PREVALENCE; STATISTICS;

HEPATITIS A VIRUS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GREECE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; VACCINATION;

EID: 62849114810     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21434     Document Type: Article

References (31)

1. Ajelli M, Iannelli M, Manfredi P, Ciofi degli Atti ML. 2008. Basic mathematical models for the temporal dynamics of HAV in medium-endemicity Italian areas. Vaccine 26:1697-1707.
2. Baaten GG, Sonder GJB, Dukers NHTM, Coutinho RA, Van den Hoek JAR. 2007. Population-based study on the Seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004. J Med Virol 79:1802-1810.
3. Basoukou-Mamasi P, Stamatopoulou G, Tsantali Ch, Danielides B. 1990. Seroepidemiological study of incidence of viral hepatitis type A at Northern Greece. Acta Microbiol Hellen 35:110-117.
4. Bell BP, Feinstone SM. 2004. Hepatitis A vaccine In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th edition. Philadelphia: WB Saunders. p 269-297.
5. Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, Fleenor M, Ryder PL, Margolis HS. 1998. The diverse patterns of hepatitis A epidemiology in the United States-Implications for vaccination strategies. J Infect Dis 178:1579-1584.
6. CDC. 1999. Prevention of hepatitis A through active or passive immunization. MMWR 48:1-37.
7. CDC. 2006. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Imunization Practices (ACIP). MMWR 55:1-23.
8. D'Amelio R, Mele A, Mariano A, Romano L, Biselli R, Lista F, Zanetti A, Stroffolini T. 2005. Hepatitis A, Italy. Emerg Infect Dis 11:1155-1156.
9. Dagan R, Leventha A, Anis E, Slatter P, Ashur Y, Shouval D. 2005. Incidence of Hepatitis A in Israel following universal immunization of toddlers. JAMA 294:202-210.
10. Dalekos GN, Zervou E, Karabini F, Tsianos EV. 1995. Prevalence of viral markers among refugees from southern Albania: Increased incidence of infection with hepatitis A, B, and D viruses. Eur J Gastrenterol Hepatol 7:553-558.
11. Frank C, Walter J, Muehlen M, Jansen A, van Treeck U, Hauri AM, Zoellner I, Rakha M, Hoehne M, Hamouda O, Schreier E, Stark K. 2007. Major outbreak of hepatitis A associated with orange juice among tourists, Egypt, 2004. Emerg Infect Dis 13:156-158.
12. Frosner GG, Papaevangelou G, Butler R, Iwarson S, Lindholm A, Courouce-Pauty A, Haas H, Deinhardt F. 1979. Antibody against hepatitis A in seven European countries. Am J of Epidemiol 110:63-69.
13. Gust ID. 1992. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine 10:S56-S58. Innis BL, Snitbhan R, Hoke CH, Munnindhorn W, Laorakpongse T. 1991. The declining transmission of hepatitis A in Thailand. J Infect Dis 163:989-995.
14. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB, Boslego JW. 1994. Protection against hepatitis A by an inactivated vaccine. JAMA 271:1328-1334.
15. Jacobsen KH, Koopman JS. 2004. Declining hepatitis A seropreva-lance: A global review and analysis Epidemiol Infect. 132:1005-1022.
16. Kremastinou J, Kalapothaki V, Trichopoulos D. 1984. The changing epidemiologic pattern ofhepatitis Ainfection in urban Greece. Am J Epidemiol 120:703-706.
17. Lee D, Cho YA, Park Y, Hwang JH, Kim JW, Kim NY, Lee DH, Lee W,Jeong SH. 2008. Hepatitis A in Korea: Epidemiological shift and call for vaccine strategy. Intervirology 51:70-74.
18. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, Rendi-Wagner P, Steffen R, Van Damme P. ad hoc travel medicine expert panel for ESENEM.2007.The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. J Travel Med 14:181-187.
19. Osborne K, Weinberg J, Miller E. 1997. The European sero-epidemio-logical network. Eurosurveillance 2:29-31.
20. Papadopoulou V, Stavrati A, Patsialis T, Papachristou A, Dimitriou M, Mamasi P. 1995. Changes in the epidemiology of acute hepatitis A during 1985-1992 period. Pediatr N Gr 7:30-34.
21. Papaevangelou G. 1992. Epidemiology ofhepatitis Ain Mediterranean countries. Vaccine 10:63-66.
22. Shapiro CN. 2003. Hepatitis A virus In: Long SL, Pickering LK, Prober CG, editors. Principles and practice ofpediatric infectious diseases. 2nd edition. London: Churchill Livingstone Inc.
23. Srinivasa Rao AS, Chen MH, Pham BZ, Tricco AC, Gilca V, Duval B, Krahn MD, Bauch CT. 2006. Cohort effects in dynamic models and their impact on vaccination programmes: An example from hepatitis A. BMC Infect Dis 6:174.
24. Van Damme P, Van Herck K. 2005. Effect of Hepatitis A vaccination programs. JAMA294:246-248.
25. Van Der Wielen M, Vertruyen A, Froesner G, Ibáñez R, Hunt M, Herzog C, Van Damme P. 2007. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: A controlled trial in children aged1-16 years. Pediatr Infect Dis J 26: 705-710.
26. Vlachos K, Karaboula A, Kattamis C. 1994. Hepatitis A vaccine and immune response. Ann Clin Paediatr 41:295-302.
27. Vogt TM, Wise ME, Bell BP, Finelli L. 2008. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 197:1282-1288.
28. Wasley A, Samandari T, Bell BP. 2005. Incidence of Hepatitis A in the United States in the era of vaccination. JAMA 294:194-201.
29. Wasley A, Grytdal S, Gallagher K, CDC. 2008. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 57: 1-24.
30. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, Ryan J, Provost P, Nalin D. 1992. A controlled trial of a formalin-inactivated hepatitis Avaccine in healthy children. N Engl J Med 327:453-457.
31. Zervou E, Dalekos GN, Alfadaki S, Lapatsanis P, Tsianos EV. 1997. Prevalence of anti-HAV IgG antibodies in paediatric population and blood donors in N.W.Greece. Acta Microbiol Hellen 42:218-222.